AN2 Therapeutics, Inc.
NASDAQ:ANTX
Overview | Financials
Company Name | AN2 Therapeutics, Inc. |
Symbol | ANTX |
Currency | USD |
Price | 1.255 |
Market Cap | 37,498,007 |
Dividend Yield | 0% |
52-week-range | 0.87 - 21.55 |
Industry | Biotechnology |
Sector | Healthcare |
CEO | Mr. Eric E. Easom |
Website | https://www.an2therapeutics.com |
An error occurred while fetching data.
About AN2 Therapeutics, Inc.
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Related Stocks
Financials
Numbers are in millions USD
Numbers are in millions USD